The findings presented in this review demonstrate that PTX3 may be a potential target for demonstrating and understanding the mechanistic impact of various therapies that address obesity-related chronic inflammation and metabolic dysfunction. This evidence concerns the gene PTX3 and obesity due to melanocortin 4 receptor deficiency.